Author	Class/Antibiotic	Dose/Regimen	COPD severity	Definition of exacerbations	Duration of treatment	Risk of bias
Suzuki 2001 (N = 109); Japan (unclear setting)	Macrolide/ Erythromycin	200 to 400 mg once daily continuous	Moderate/severe FEV₁ 1.38 L at baseline	Acute and sustained worsening of COPD symptoms requiring changes to regular treatment, including antimicrobial therapy and/or short courses of systemic steroids Mild/moderate exacerbation: treatment without hospitalisation Severe exacerbation: requiring hospitalisation	52 weeks	Study was not blinded, high risk of bias for performance and detection domains, funding not stated